Trial reportLeukemia2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.
Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, Jiří Mayer, Arpad Illes, Anna Angona Figueras, Alexander Kiani, Aude Charbonnier, Theodoros Marinakis, Leif Stenke and 6 more
Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
In one paragraphTrial report in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Delphine ReaService d'Hématologie Adulte, Hôpital Saint-Louis APHP, Paris, France. delphine.rea@aphp.fr.ORCID 0000-0001-5379-7461 Slawomira Kyrcz-KrzemienDepartment of Hematology and BMT, Silesian Medical University Hospital SPSKM, Katowice, Poland.
Paolo SportolettiDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato-Oncological Research, University of Perugia, Perugia, Italy.
Jiří MayerDepartment of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital, Brno, Czechia.ORCID 0000-0003-0567-9887 Arpad IllesDepartment of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Anna Angona FiguerasHospital Josep Trueta - Institut Català d'Oncologia, Girona, Spain.
Alexander KianiDepartment of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, and Comprehensive Center Erlangen EMN, Erlangen, Germany.ORCID 0000-0002-2494-4087 Theodoros MarinakisDepartment of Clinical Hematology, G. Gennimatas Hospital, Athens, Greece.
Leif StenkeHematology Center, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Andrzej HellmannDepartment of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
Peter SchuldNovartis Pharma AG, Basel, Switzerland.
Gianantonio RostiIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS "Dino Amadori", Meldola, Italy.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The phase 3 ENESTPath study investigated treatment-free remission (TFR) rates in patients with chronic Philadelphia chromosome-positive (Ph+) and/or BCR::ABL1
Indexed as
Antineoplastic AgentsImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositivePyrimidinesAdolescentAdultAgedAged, 80 and overConsolidation ChemotherapyFemaleFusion Proteins, bcr-ablHumansMaleMiddle AgedProtein Kinase InhibitorsRemission InductionAntineoplastic AgentsFusion Proteins, bcr-ablImatinib MesylatenilotinibProtein Kinase InhibitorsPyrimidines
What OpenQuestion holds
Textmetadata
Read underepoch 390